CancerVax, Serono partner for Canvaxin development
CancerVax (cancer therapeutics) and Serono SA have entered into an agreement to further develop CancerVax's Canvaxin, a Phase III immunotherapeutic to treat advanced-stage melanoma.
- Gene Therapy, Cell Therapy
- Includes Equity
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.